 The Sonablate 500 is a revolutionary device that is used to treat prostate cancer and BPH. It uses High Intensity Focused Ultrasound (HIFU) treat these conditions. It is the first and only truly non-invasive procedure for treating prostate cancer. Patients do not have to have a TURP procedure or any other surgery prior to treatment with the Sonablate.
The Sonablate works by delivering the ultrasound waves through a single transducer. The HIFU waves are delivered into a targeted area of the prostate, the focal point, and this raises the temperature of the tissues in the gland to 90 degrees Celsius very quickly. This destroys the tissues in that area, and the doctor can move the treatment to the next focal point.
The same transducer that delivers the treatment also captures images of the prostate in real-time, which allows the doctor to pinpoint the areas of treatment on an individual patient basis. With this real-time imaging technology, no two patients receive the same treatment. The Sonablate divides the prostate into six treatment zones, and then uses the ultrasound waves to ablate the entire prostate gland, effectively destroying the cancer as well.
Prostate cancer treatment with the Sonablate 500 starts with the doctor capturing initial images of the prostate. These images are used to plan out the treatment using Simul-Plan Therapy Planning. Once the treatment is planned, the same transducer delivers split beam HIFU to the targeted areas with a click of the mouse. The images are continually updated so that the doctor can change the treatment as the glad begins to be destroyed.
The technology powering the Sonablate 500 began at the Indiana University School of Medicine in Indianapolis in the 1970s. Further development and research has gone on in research centers around the world. Today, HIFU using the Sonablate 500 is the best choice for HIFU, and there are nearly 100 HIFU centers across the globe that are using the device to treat their patients.
The Sonablate® 500 is being studied in clinical trials for use in the treatment of prostate cancer in the United States and is not approved for use by the U.S. Food and Drug Administration. HIFU with the Sonablate® 500 is authorized for use for the treatment of prostate cancer in Canada, Argentina and the Dominican Republic. It is also available in the Bahamas and Mexico.
|
|
|
